Conning Inc. Jounce Therapeutics, Inc. Transaction History

Conning Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2018 May 04, 2018	SELL	$13.4 - $28.4 $1.69 Million - $3.58 Million	-125,960 Closed	0 $0
Q3 2017 Oct 20, 2017	BUY	$11.17 - $16.99 $1.41 Million - $2.14 Million	125,960	125,960 $1.96 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Conning Inc., based on Form 13F filings with the SEC.

Stay updated on Conning Inc. with notifications on news.